Calcineurin inhibitors (CNIs) frequently induce neurological complications early after orthotopic liver transplantation (OLT). We hypothesize that longterm CNI therapy after OLT causes dose-dependent cognitive dysfunction and alteration of brain structure. In this study, 85 OLT patients (20 with CNI-free, 35 with CNI low-dose, and 30 with standard-dose CNI immunosuppression) underwent psychometric testing and cerebral magnetic resonance imaging approximately 10 years after OLT to assess brain function and structural brain alterations. A total of 33 healthy patients adjusted for age, sex, and education served as controls. Patients receiving CNI showed a significantly worse visuospatial/constructional ability compared with controls (P £ 0.04). Furthermore, patients on low-dose CNI therapy had an overall impaired cognitive function compared with controls (P 5 0.01). The tacrolimus total dose and mean trough level were negatively correlated to cognitive function. CNI doses had been adjusted in 91% of the patients in the low-dose and CNI-free groups in the past due to CNI-induced kidney damage. Patients treated with CNI showed significantly more white matter hyperintensities (WMH) than patients on CNI-free immunosuppression and controls (P < 0.05). Both the mean cyclosporine A and tacrolimus trough levels correlated significantly with WMH. In conclusion, longterm CNI therapy carries a risk of cognitive dysfunction especially in patients who already showed nephrotoxic side effects indicating an increased susceptibility of these patients against toxic CNI effects. This subgroup of patients might benefit from a change to CNI-free immunosuppression.
Orthotopic liver transplantation (OLT) requires lifelong immunosuppression, which is usually composed of calcineurin inhibitors (CNIs; cyclosporine or tacrolimus), mycophenolate mofetil, and steroids. (1) The development of immunosuppressive therapy regimens based on CNI led to significantly increased survival rates after OLT. (2) In consequence, longterm adverse effects of CNI therapy gained increased importance. Renal dysfunction, malignancy, and cardiovascular disease are predominantly considered, each affecting approximately 25% of the patients 10 years after OLT. (3) Interestingly, data about the longterm effects of CNI on the central nervous system are sparse although neurotoxic side effects of CNI are known especially for the first weeks after OLT. (4, 5) Within the first weeks after OLT, approximately 30% of the patients present with neurological symptoms like disorientation, hallucinations, cognitive dysfunction, alterations of consciousness, and seizures, which are generally considered as being caused by CNI therapy. (6) So far, those few studies that addressed the longterm effect of CNI on the central nervous system Abbreviations: AH, arterial hypertension; AIH, autoimmune hepatitis; ALF, acute liver failure; ANOVA, analysis of variance; BDI, Beck's Depression Inventory; BMI, body mass index; CI, confidence interval; CNI, calcineurin inhibitor; DM, diabetes mellitus; GFR, glomerular filtration rate; HBV, hepatitis B virus; HC, hypercholesterolemia; HCV, hepatitis C virus; HE, hepatic encephalopathy; IQR, interquartile range; MRI, magnetic resonance imaging; n.a., not applicable; NASH, nonalcoholic fatty liver disease; OLT, orthotopic liver transplantation; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; PTE, posttransplant encephalopathy; PVH, periventricular hyperintensities; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SD, standard deviation; VWCN, ventricular width at the level of the caudate nucleus; VWSC, ventricular width at the level of the semioval center; WMH, white matter hyperintensities.
showed cognitive impairment and brain atrophy. (7) (8) (9) These studies comprised 10-22 patients approximately 6-12 years after OLT. Possible causes for brain dysfunction in consequence of longterm CNI therapy are premature atherosclerosis and microangiopathy due to an excess of cardiovascular risk factors such as hypertension and diabetes, (10) chronic impairment of the cerebral mitochondrial energy metabolism by CNI, (11, 12) and/or an alteration of the cerebral immune system with consecutive neurodegeneration. (11) Several studies addressed whether reduction of CNI improves longterm patient outcome. Adding mycophenolate mofetil accompanied by a dose reduction of CNI in OLT recipients has, for example, led to a recovery of renal function. (13) (14) (15) However, the effect of CNI reduction or withdrawal on further longterm sequelae of CNI therapy has not been examined so far. Evidence for significant longterm neurotoxicity of the standard CNI-based immunosuppression after OLT would suggest a preference for CNI-free maintenance therapy in the future as long as the transplant function is preserved. (16) This single-center observational study investigated the dose-dependent chronic neurotoxicity of CNI in patients after liver transplantation. We hypothesize that patients on longterm CNI therapy in standard dosage present increased numbers of white matter hyperintensities (WMH) and periventricular hyperintensities (PVH), increased ventricular width, and show impaired cognitive function compared with patients receiving a reduced CNI dose, patients with CNI-free immunosuppression, and controls.
Patients and Methods

PATIENTS
In total, 1045 patients registered in the database of the Hannover Medical School liver transplantation outpatient clinic were screened for eligibility. Patients with an OLT more than 2 years ago, age between 18 and 80 years, with German as their native language, and on a stable immunosuppressive therapy regimen fulfilled the inclusion criteria. Exclusion criteria were an additional transplantation of other organs; liver retransplantation (>3 months after first OLT); neurological or psychiatric diseases; regular intake of drugs affecting brain function; contraindications for magnetic resonance imaging (MRI); acute transplant rejection or acute infection; and decompensated heart, liver, or kidney function. After application of the inclusion and exclusion criteria, 375 of 1045 patients remained available for study participation. Of these, 51 were on a CNI-free immunosuppression and thus were addressed first. Twenty patients of this group agreed to participate. The eligible patients on standard-dose and low-dose CNI therapy comparable in age, education, and time interval since transplantation to those on CNI-free immunosuppression were asked to participate in the study. It was intended to assess approximately 30 patients per group. Finally, 91 patients were examined. After excluding several patients from the present analysis due to a regular intake of brain affecting medication (n 5 3), decompensated kidney function (n 5 2), and incomplete psychometric testing (n 5 1; Fig. 1 ), 85 patients (age 58.2 6 9.8 years, n 5 56 [65.9%] male) in whom OLT had been performed approximately 10 years ago (median, 10 years; IQR, 8.0-13.5 years) were finally included. The patients were subdivided according to their immunosuppressive therapy regimen into patients with CNIfree immunosuppression (n 5 20; group 1), patients on low-dose CNI therapy (n 5 35; group 2; stable tacrolimus trough levels below 5 mg/L or stable cyclosporine A trough levels below 50 mg/L), and patients on standard-dose CNI therapy (n 5 30; group 3; stable tacrolimus trough levels above 5 mg/L or stable cyclosporine A trough levels above 50 mg/L). Of the 65 patients treated with CNI, 8 patients received only CNI for immunosuppression, whereas 57 were additionally treated with at least 1 further immunosuppressant. A total of 25 were additionally treated with mycophenolic acid, 8 with prednisolone, 21 with mycophenolic acid and prednisolone, and 3 with prednisolone and azathioprine. The patients with currently CNI-free immunosuppression had been treated for 4.2 6 3.8 years with CNI after OLT and were CNI-free for 8.0 6 2.8 years at the time point of inclusion. The maintenance therapy consisted of sirolimus and mycophenolic acid (n 5 2); sirolimus and prednisolone (n 5 2); sirolimus, mycophenolic acid, and prednisolone (n 5 2); everolimus (n 5 1); everolimus and mycophenolic acid (n 5 1); mycophenolic acid and prednisolone (n 5 11); or mycophenolic acid (n 5 1). Thirty-three controls (age 58.6 6 7.9 years, n 5 15 [45%] male; group 4) adjusted for age, sex, and education served as a control group. All patients gave written informed consent. The study was approved by the local ethics committee and performed according to the World Medical Association Declaration of Helsinki (revised in 2008).
METHODS
All patients underwent a standardized physical neurological examination performed by a neurologist of the group. Age, sex, underlying liver disease, presence of arterial hypertension (AH), diabetes mellitus (DM), chronic kidney disease grade III, or hypercholesterolemia (HC) as well as body mass index (BMI), medication, history of hepatic encephalopathy (HE), history of posttransplant encephalopathy (PTE; metabolictoxic-caused neurological complications after OLT such as disorientation, confusion, hallucinations, cognitive dysfunction, and seizures), years of education, years since OLT, years on standard-dose CNI, CNI dosages and CNI trough levels of each visit at the outpatient clinic, and current glomerular filtration rate (GFR) were assessed and documented from anamnesis and case records. The mean CNI trough level and the total CNI dosage for each patient were calculated with last observations carried forward between each measuring point between OLT and the study examination date. CNI trough levels and dosages were documented, and the days between each measured CNI trough level and dosage were calculated. Each CNI trough level and dose was then multiplied with the number of days it was in effect until the next CNI measurement or the study examination date and added up to the total CNI level and dose, respectively. Finally, to generate the mean CNI trough level, the calculated total CNI level was divided by the number of days between OLT and study examination date. Five patients with current CNI-free immunosuppression had a history of cyclosporine A and tacrolimus therapy. Thus, for these patients, a total dose and mean trough level exists for both cyclosporine A and tacrolimus. In 3 patients, the calculation of the mean CNI trough level and in 2 patients the calculation of the CNI total dose was not possible.
Psychometric Testing and Beck's Depression Inventory
All patients performed the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (17) (18) (19) and completed Beck's Depression Inventory (BDI) (for description see Supporting Text 1). (20) 
Magnetic Resonance Imaging
For a semiquantitative assessment of the cerebrovascular lesion load and alterations of brain volume, cerebral MRI was performed at 3T (Verio, Siemens, Erlangen, Germany) with a standard quadrature head coil. The MRI protocol consisted of a high-resolution T 1 -weighted 3-D magnetization-prepared rapid gradient-echo sequence, an axial T 2 -weighted turbo spin echo sequence, an axial turbo inversion recovery magnitude sequence, and an axial T 2* -weighted gradient-echo sequence.
The Scheltens scale, as a standardized semiquantitative visual analysis method for the assessment of PVH and WMH, was applied (for details see Supporting Text 2). (21) Additionally, the ventricular width at the level of the caudate nucleus (VWCN) and ventricular width at the level of the semioval center (VWSC) were measured in millimeters (Fig. 2) .
MRI values are missing for 1 patient and 1 control due to abortion of the MRI measurement. A backward multivariate linear regression analysis was applied to identify independent prognostic factors for cognitive function considering the RBANS sum score and total scale as dependent variables and age, education in years, years since OLT, years on standard-dose CNI, GFR, AH, DM, HC, VWNC, VWSC, and total WMH as independent factors. In an additional analysis, cyclosporine A total dose and mean trough level or tacrolimus total dose and mean trough level were included as independent variables. The regression coefficient, P value, and 95% confidence interval (CI) are displayed. Normally distributed values are shown as mean 6 standard deviation (SD), not normally distributed values are shown as median (IQR). A P value of 0.05 was considered significant for all tests applied. The statistical calculations were performed with SPSS, version 24 (IBM, Armonk, NY).
STATISTICAL METHODS
Normality of distribution was assessed by the
Results
CHARACTERISTICS OF PATIENTS AND CONTROLS
In the neurological examination, tremor was detected in 5 (6%) of 85 patients. Otherwise, the neurological status was normal in all patients. The patient groups and controls did not differ significantly in all characteristics registered. Concerning the values only applicable for the patient groups, the current GFR was significantly lower in patients receiving a CNI-free immunosuppression compared with patients on standard-dose CNI therapy (P 5 0.01). And, as expected, the time period on standard-dose CNI therapy was significantly longer in patients receiving standard-dose CNI therapy compared with patients on CNI-free (P 5 0.001) as well as low-dose CNI (P 5 0.02) immunosuppression (Table 1 ). The main reason for the reduction or termination of CNI therapy was CNI-induced kidney damage (Fig. 3) . In 5 of 35 (14%) patients now receiving a low-dose CNI therapy, the reduction was initiated because of good graft function (n 5 4) or posttransplant diabetes (n 5 1). In the remaining 30 patients on a low-dose CNI therapy and in all of the 20 patients on a CNI-free immunosuppression, the reason for therapy adjustment or termination was CNI-induced kidney damage.
RBANS AND BDI
The median BDI of patients and controls was within the normal range, and the groups did not differ significantly. A total of 7 (8%) patients (CNI-free, n 5 standard-dose CNI, n 5 2 [of 30; 6.7%]); and 2 (6.1%) controls had a pathological RBANS test result (percentile < 10%). Considering the median results, the patients with a CNI-free immunosuppression did not differ from controls in any domain of the RBANS. Patients on standard-dose CNI therapy (P 5 0.04) and patients on low-dose CNI therapy (P 5 0.01), however, showed significantly worse results in the visuospatial/constructional ability compared with controls (Fig. 4) . Furthermore, patients on low-dose CNI therapy showed significantly worse results in the RBANS sum score (P 5 0.02), RBANS total scale (P 5 0.01), and RBANS percentile (P 5 0.03) compared with controls ( Table 2 ). The analysis after exclusion of the 5 patients receiving CNI low-dose therapy due to other reasons than CNI-induced kidney damage showed similar results. Patients on low-dose CNI therapy still showed significantly worse results in the RBANS domain score visuospatial/constructional ability (P 5 0.02), the RBANS sum score (P 5 0.03), RBANS total scale (P 5 0.02), and RBANS percentile (P 5 0.04) compared with controls. Our results indicate that patients receiving a low-dose CNI immunosuppression due to CNIinduced kidney damage show impaired cognitive function compared with controls. The years on standard-dose CNI therapy correlated negatively with the RBANS sum score (n 5 85; r 5 20.2; P 5 0.04); the tacrolimus total dose showed a significant negative correlation to the RBANS sum score (n 5 36; r 5 20.4; P 5 0.04), total scale (r 5 20.4; P 5 0.04), and percentile (r 5 20.4; P 5 0.04); NOTE: P value 0.05 is considered significant. *Overall between groups. † ALF: drug-induced, n 5 2; unknown reason, n 5 4. ‡ Others: hepatocellular carcinoma, n 5 7; other liver tumor, n 5 3; NASH with hepatocellular carcinoma, n 5 2; polycystic liver disease, n 5 8; secondary cholangitis, n 5 3; Budd-Chiari syndrome, n 5 2; Wilson's disease, n 5 1; Caroli syndrome, n 5 2; disturbed arterial blood flow, n 5 1. and the tacrolimus mean trough level showed a significant negative correlation to the RBANS domain score immediate memory (n 5 35; r 5 20.5; P 5 0.01), sum score (r 5 20.4; P 5 0.01), total scale (r 5 20.4; P 5 0.01), and percentile (r 5 20.4; P 5 0.02). No significant correlations were observed between the RBANS domain scores and age, BMI, years since OLT, cyclosporine A total dose, or cyclosporine A mean trough level. The correlation analysis showed that the time period on standard-dose CNI therapy and especially tacrolimus are associated with reduced cognitive test performance.
MAGNETIC RESONANCE IMAGING
The whole patient group showed significantly more WMH in the parietal (2.0 6 1.9 versus 1.2 6 1.9; P 5 0.02) and temporal (0.4 6 0.8 versus 0.1 6 0.2; P 5 0.04) region than healthy controls. Patients treated with CNI showed significantly more WMH in the parietal region than controls (low-dose CNI 2.1 6 2.1 and standard-dose CNI 2.2 6 1.9 versus controls 1.2 6 1.9; P 0.03). Occipital WMH were not detected in patients with CNI-free immunosuppression. The other treatment groups (low-dose CNI, 1.0 6 1.3; standard-dose CNI, 0.6 6 1.1) and controls (0.6 6 1.3) had significantly more occipital WMH (P < 0.04) than patients on CNI-free immunosuppression. WMH in the temporal region were significantly more frequent in patients on standard-dose CNI therapy compared with patients with CNI-free immunosuppression (0.5 6 0.8 versus 0.1 6 0.2; P 5 0.02) as well as controls (0.5 6 0.8 versus 0.1 6 0.3; P 5 0.01). The frontal and total WMH showed no significant group differences (Fig. 5) . All patients as a group had a significantly broader VWSC than controls (33.1 6 6.2 versus 30.2 6 5.6; P 5 0.01). However, considering the different treatment groups, no significant difference was found for ventricular width at both measurement locations. The PVH adjacent to the lateral ventricles showed no significant group differences. Our results indicate that CNI 
LINEAR REGRESSION
The univariate analysis showed a significant impact of education in years (P 5 0.001), VWCN (P < 0.03), and years on standard-dose CNI (P 5 0.04) on the RBANS scores.
Backward multivariate regression analysis showed that education in years (n 5 84; regression coefficient 5 10.7; P 5 0.001; 95% CI, 4.6-16.9), VWCN (regression coefficient 5 22.8; P 5 0.02; 95% CI, 25.3 to 20.4), and years of standard-dose CNI therapy (regression coefficient 5 22.0; P 5 0.038; 95% CI, 23.8 to -0.1) were independent prognostic factors for the RBANS sum score. Concerning the RBANS total scale education in years (regression coefficient 5 2.8; P 5 0.001; 95% CI, 1.2-4.4) and VWCN (regression coefficient 5 20.8; P 5 0.02; 95% CI, 21.4 to 20.1) were independent prognostic factors.
Backward multivariate analysis in the group of patients treated with cyclosporine A (n 5 51) showed that VWCN was a significant negative prognostic factor for the RBANS sum score (regression coefficient 5 24.3; P 5 0.005; 95% CI, 27.1 to 21.4) and total scale (regression coefficient 5 21.1; P 5 0.005; 95% CI, 21.9 to 20.4). Education in years was a positive prognostic factor for the RBANS sum score (regression coefficient 5 13.5; P 5 0.001; 95% CI, 5.6-21.4) and total scale (regression coefficient 5 3.5; P 5 0.001; 95% CI, 1.4-5.6). In the group of patients treated with tacrolimus (n 5 35), the total dose was a significant negative prognostic factor for the RBANS sum score (regression coefficient 5 20.002; P 5 0.005; 95% CI, 20.003 to 20.001). In summary, the regression analysis showed that CNI therapy is a negative independent prognostic factor for cognitive function.
Discussion
So far, the knowledge about the impact of longterm CNI therapy after OLT on the central nervous system is limited. Thus, the aim of this observational study was to evaluate the impact of longterm CNI therapy upon the brain by assessing cognitive function and cerebral structural alterations. Our results indicate that longterm CNI therapy after OLT may induce both cognitive dysfunction and structural brain alterations.
Before OLT many patients with chronic liver disease suffer from cognitive impairment caused by HE. (22) It is assumed that after OLT, HE-associated cognitive dysfunction recovers. Ahluwalia et al. showed an improvement of cognitive function and cerebral magnetic resonance spectroscopy from before OLT to 6 months after OLT in 66 patients of which 38 had a history of HE before OLT. (23) However, 21% of the patients still showed cognitive impairment after OLT. Campagna et al. as well showed cognitive improvement 9-12 months after OLT in 65 patients of which 23 had a history of HE before OLT. The patients with HE history showed a greater improvement after OLT than those without, but their global cognitive function remained slightly impaired. (24) Our group as well showed a continuous improvement of cognitive function 6 and 12 months after OLT in patients with a history of HE before OLT. However, patients LIVER TRANSPLANTATION, Vol. 24, No. 1, 2018 PFLUGRAD ET AL.
without pretransplant HE showed a cognitive decline after transplant. (25) The features of cognitive impairment after OLT were different from those known to occur in HE before OLT. It was concluded that OLT improves HE-associated cognitive impairment, whereas after transplant, a differently caused newonset alteration of brain function occurs in some patients. Because CNIs are known to have neurotoxic side effects-which were shown in vitro (11, 12) and in vivo especially during the first weeks after OLT (4, 6) -it was obvious to consider longterm CNI therapy as a possible cause of new-onset cognitive decline after OLT. Interestingly, only sparse data are available in this respect.
Lewis and Howdle (7) showed cognitive impairment in a wide range of cognitive functions and reduced health-related quality of life in 12 patients approximately 12 years after OLT compared with controls. Longterm cognitive impairment after OLT was also shown by Senzolo et al. (8) who additionally assessed cerebral glucose metabolism. Of 14 patients examined before OLT, 12 were assessed again 1 year after OLT and 7 again 10 years after OLT. Cognitive function and cerebral glucose metabolism improved within 1 year after OLT and were constant 10 years after OLT. However, 20% of the patients still showed deficits in frontal tasks.
In contrast, Mattarozzi et al. described an improvement of cognitive function in 12 patients within 18 months after OLT, which sustained in a longterm follow-up examination between 7 and 10 years after OLT. (26) The contradicting interpretation of longterm cognitive performance after OLT between these studies might be explained by differences in patient selection, low patient numbers, or missing healthy control group. Hence, our study aimed to assess the assumed CNIassociated longterm cognitive decline after OLT in a larger patient group with a healthy control group adjusted for age, sex, and education for comparison. To investigate a possible dose dependency, the patients were subdivided according to their immunosuppressive therapy regimen. Our data indicate as well longterm cognitive decline in patients receiving CNI-based immunosuppression approximately 10 years after OLT. Interestingly though, patients on a reduceddose CNI therapy regimen especially showed an overall impaired cognitive function compared with controls. This patient group did not differ from the other patient groups concerning basic parameters displayed in Table 1 . However, patients now receiving a CNI low-dose CNI therapy had had an adjustment of their maintenance therapy after OLT, which distinguishes them from patients on standard-dose CNI therapy. Of the patients receiving low-dose or CNI-free immunosuppression, 91% were taken off CNI therapy or had their CNI dose reduced due to CNI-induced kidney damage. CNIs are known to impair kidney function, (27) which led to a discussion about minimization of CNI dose after transplantation. Our results indicate that especially patients receiving low-dose CNI therapy after showing nephrotoxic side effects in the past now present with cognitive alterations. This hints at an increased susceptibility against toxic CNI effects in this subgroup of patients, and continuation of CNI therapy despite toxic side effects seems to result in metabolic alterations of the brain and cognitive dysfunction in the long term. Although only 11.4% of the patients in the low-dose CNI group had a pathological RBANS test result, this result should be taken seriously as the group comparisons indicate worse test performance in these patients compared with controls. Further studies should address this in the future.
The correlation analysis between CNI total dosage and mean trough level and RBANS results suggests an increased neurotoxicity of tacrolimus than of cyclosporine A. However, we found as well that both cyclosporine A and tacrolimus mean trough levels correlated with WMH, indicating a similar effect on brain structure for both drugs. A higher neurotoxicity of tacrolimus compared with cyclosporine A was previously described. (28) However, studies showed differing results in this respect indicating a comparable neurotoxicity of tacrolimus and cyclosporine A (29) or even a lower toxicity of tacrolimus concerning renal function and vascular toxicity (30) or impairment of the mitochondrial energy metabolism. (31, 32) Longterm CNI therapy can induce premature atherosclerosis and microangiopathy due to an excess of cardiovascular risk factors. (10) Therefore, CNI can be expected to induce cerebrovascular events and thus cause brain dysfunction. Garc ıa Mart ınez et al. assessed ventricular size and the volume of T 2 white matter lesions with MRI besides cognitive function in 22 patients before OLT, 6-12 months and 6-9 years after OLT compared with 13 healthy controls. (9) At both points in time after OLT patients showed brain atrophy, structural brain alterations, and slight cognitive impairment compared with controls. The authors hypothesized that short-term brain atrophy after OLT is caused by resolution of cirrhosis-related brain edema, whereas longterm brain atrophy after OLT might be caused by vascular risk factors. The same group suggested that HE episodes before OLT impair cognitive function 1 year after OLT. (33) We as well found an increased VWSC indicating brain atrophy in patients after OLT compared with controls. Furthermore, patients showed more WMH compared with controls, and in addition, longterm CNI therapy after OLT is associated with increased numbers of WMH. The negative effect of longterm CNI therapy on brain structure is underlined by our correlation analysis. As expected, patients with diabetes showed significantly more parietal WMH (P 5 0.02) and patients with HC increased VWCN (P 5 0.02) than those without. However, as shown in Table 1 , AH, DM, HC, and history of HE are equally distributed between our patient groups. Thus, vascular risk factors and history of HE cannot solely explain longterm brain atrophy in patients after OLT. Our results indicate that longterm CNI therapy is associated with microangiopathic brain lesions and cognitive dysfunction. The pathomechanism of CNI-induced toxicity, however, is complex. Discussed are microangiopathy, (10) impairment of the cerebral mitochondrial energy metabolism, (12) and neurodegeneration induced by alteration of the cerebral immune system. (11) Our findings underline that CNI-induced microangiopathy is probably involved in the development of longterm cognitive dysfunction in patients after OLT. However, especially patients with low-dose CNI treatment present with longterm cognitive impairment. Hence, high CNI dosage and trough levels cannot solely explain longterm cognitive dysfunction in these patients. Thus, other pathomechanisms need to be further investigated in the future.
Our study is limited by being a single-center study, which might restrict the transferability to other centers. Another restriction is that we had no data from before OLT from our patients for comparison except in 6 (7%) patients (see Supporting Table 1 ). Furthermore, the CNI-free group received a CNI-based immunosuppression directly after OLT. Unfortunately, patients with a complete CNI-free immunosuppression after OLT were unavailable. It should be emphasized that our patients had stopped CNI treatment for 8.0 6 2.8 years at inclusion. Furthermore, some patients received an immunosuppressant additionally to CNI. This limitation was impossible to control because most patients after OLT receive a combination therapy.
In conclusion, our results suggest that longterm CNI therapy may induce neurotoxic effects especially in patients who present with nephrotoxicity with tacrolimus seeming to be more neurotoxic than cyclosporine A. After the occurrence of nephrotoxic side effects, continuation of CNI therapy-even in a low dosemight carry the risk for cognitive alterations in the long term, indicating an increased susceptibility against toxic CNI effects in this subgroup of patients. As long as transplant function is preserved, patients showing CNI toxicity early after OLT might benefit from a change to CNI-free immunosuppression in the long term because cognitive dysfunction might impair patients' everyday life, job-related performance, and health-related quality of life.
